Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $25 to $28.
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $25 to $28.